Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome.
肺癌中埃罗替尼—结果的分子和临床预测。
In addition, erlotinib is an oral agent, so it is more convenient to administer than IV chemotherapy.
此外，埃罗替尼是一种口服药，因此，在给药方面较静脉注射化疗药物更为方便。
Grade 3 or greater elevations of AST were reported in 11 and 8% of patients receiving erlotinib and placebo, respectively.
应用厄罗替尼布和安慰剂组都有11(8%)名患者出现3级或更高的AST升高。
Erlotinib is also being evaluated in combination with capecitabine in patients who failed first-line therapy with gemcitabine.
厄罗替尼布联合卡培他滨同样用于一线药物吉西他滨治疗失败的患者。
ObjectiveTo evaluate the efficacy, clinical benefits and toxicities of gemcitabine combined with erlotinib for advanced pancreatic cancer.
目的观察吉西他滨联合厄洛替尼方案治疗进展期胰腺癌的疗效、临床获益反应和毒性反应。
The response rate to erlotinib therapy was similar in patients with tumor-only mutations and in those with tumor and serum mutations (67%).
对埃罗替尼治疗的反应率，仅在肿瘤组织中存在变异的患者和那些肿瘤和血浆中均存在变异的患者是相似的(67%)。
The largest disparities were in the use of the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed, the study found.
差别最为悬殊的是新型抗结肠直肠癌及肺癌药物的应用，这些药物包括贝伐单抗、西妥昔单抗、埃罗替尼及培美曲塞。
To evaluate the clinical efficacy and the security of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer and COPD.
评价单药厄洛替尼治疗晚期非小细胞肺癌合并COPD患者的疗效和安全性。
Conclusion For elderly patients with advanced non-small cell lung cancer and COPD, the use of erlotinib might achieve better security and effectiveness.
结论厄洛替尼单药对晚期非小细胞肺癌合并COPD的患者不良反应小，耐受性好，疗效可接受。
For example, the use of bevacizumab for colorectal cancer and erlotinib for lung cancer in the United States was 10 times higher than the European average.
例如，美国应用贝伐单抗治疗直肠结肠癌以及埃罗替尼治疗肺癌是欧洲平均水平的10倍。
Fortuitously, these drugs also have clinically obvious pharmacodynamic end points-hypertension for bevacizumab and skin toxicity for erlotinib and gefitinib.
例外的是，这些药物也有临床明显的药物副作用——贝伐单抗可致高血压，吉非替尼和厄洛替尼可有皮肤毒性。
The patients received bevacizumab intravenously once every two weeks for four weeks and took erlotinib orally every day for eight weeks before they had surgery.
在术前，患者每两周一次静脉接受贝伐单抗，持续四周；同时，每天口服埃罗替尼，持续八周。
Treatment with bevacizumab plus gemcitabine-erlotinib was well tolerated: safety data did not differ from previously described safety profiles for individual drugs.
吉西他滨-厄洛替尼联合贝伐单抗治疗有很好的耐受性：得到的安全数据和先前描述的个性化药物治疗得到的安全数据不同。
Conclusion the effect of the concomitant of erlotinib and WBRT in patients of NSCLC with brain metastases is better than WBRT alone, and the concomitant therapy is well tolerated.
结论厄洛替尼联合全脑放疗对非小细胞肺癌脑转移灶的疗效高于单纯全脑放疗，且毒副反应可以耐受。
It should be noted that the ATLAS patient population had almost no squamous cell carcinoma, in contrast to the populations of the JMEN pemetrexed trial and the SATURN erlotinib trial.
值得注意的是ATLAS试验纳入的绝大多数病人为非鳞状细胞癌，不同于培美曲赛的JMEN试验和厄洛替尼的SATURN试验。
Also the combination of different target agents, such as combining the EGFR blockers - such as erlotinib and the cyclooxygenase-2 inhibitor (celecoxib) - needs to be investigated in clinical trials.
联合应用靶向因子如egfr阻滞剂-如厄罗替尼布和环氧化酶2抑制因子(塞来考昔)-还需要临床验证。
Also the combination of different target agents, such as combining the EGFR blockers - such as erlotinib and the cyclooxygenase-2 inhibitor (celecoxib) - needs to be investigated in clinical trials.
联合应用靶向因子如egfr阻滞剂-如厄罗替尼布和环氧化酶2抑制因子(塞来考昔)-还需要临床验证。
应用推荐